These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24247716)

  • 1. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
    Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
    Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
    Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer.
    Turo R; Tan K; Thygesen H; Sundaram SK; Chahal R; Prescott S; Cross WR
    Urol Int; 2015; 94(3):307-12. PubMed ID: 25342383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diethylstilbestrol in castration-resistant prostate cancer.
    Wilkins A; Shahidi M; Parker C; Gunapala R; Thomas K; Huddart R; Horwich A; Dearnaley D
    BJU Int; 2012 Dec; 110(11 Pt B):E727-35. PubMed ID: 23110500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current role of diethylstilbestrol in the management of advanced prostate cancer.
    Bosset PO; Albiges L; Seisen T; de la Motte Rouge T; Phé V; Bitker MO; Rouprêt M
    BJU Int; 2012 Dec; 110(11 Pt C):E826-9. PubMed ID: 22578092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
    Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
    Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
    Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
    Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
    Omlin A; Pezaro CJ; Zaidi S; Lorente D; Mukherji D; Bianchini D; Ferraldeschi R; Sandhu S; Dearnaley D; Parker C; Van As N; de Bono JS; Attard G
    Br J Cancer; 2013 Sep; 109(5):1079-84. PubMed ID: 23928659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
    Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
    Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
    Saad F; Segal S; Eastham J
    Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
    Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
    BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
    Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF
    J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.